Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib vs intravesical chemotherapy in high-risk NMIBC with FGFR alterations
jRCT2080225050Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial of erdafitinib in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) (3 arms), sponsored by Janssen Pharmaceutical. Started Feb 2020; status: completed.
02
Drugs
erdafitinib
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT2080225050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225050.